IGC.US IGC Pharma, Inc.

Healthcare Trading Companies & Distributors USA Stocks
0.1760 USD
Close of Nov 14, 2026
0.1700 0.3600
Market cap
USD 20.5M
P/E
-
P/B
3.16x
ROE
-153.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is IGC.US undervalued?

Graham number

The Graham number of IGC Pharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IGC Pharma, Inc. fundamental analysis

No fundamental analysis for IGC Pharma, Inc. yet.

IGC Pharma, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IGC Pharma, Inc.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, th…

Full company profile